Navigation Links
BiOptix Announces Additional $1.4M in Funding to Aid in Commercialization and Working Capital Needs
Date:8/13/2014

BOULDER, Colo., Aug. 13, 2014 /PRNewswire/ -- BiOptix announced today an additional $1.4M financing from existing investors.  The funds will be used to expand sales and marketing and ramp up manufacturing to meet growing customer demand. 

Rick Whitcomb, President and CEO of BiOptix, noted:  "This latest increase in capital shows that our investors are confident in our plan and our team, and that BiOptix is on a solid path to commercial success."  BiOptix continues to see opportunity in the label-free marketplace, which is looking for a high quality, high performance SPR instrument at a reasonable price. "We are making great inroads in the marketplace, and this infusion of capital will aid our efforts to reach as many scientific researchers as possible," commented Whitcomb.

Surface Plasmon Resonance (SPR) is an advanced and highly sensitive optical technology that measures refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon Resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix marries the high sensitivity of SPR with the high stability and lower noise of common path interferometry.

About BiOptix

BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at:  www.bioptix.com


'/>"/>
SOURCE BiOptix
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. BiOptix announces expansion of Innovators Program into Europe
2. BiOptix announces low cost Surface Plasmon Resonance Services for Colorado-based researchers
3. BiOptix to highlight new carbonic anhydrase data at IBCs Biopharmaceutical Development & Production Week
4. BiOptix announces expansion of Innovators Program at Molecular Med TRI-CON 2013
5. BiOptix Announces Fall 2012 Tradeshow and Symposia Schedule
6. Perrigo Company plc Announces Quarterly Dividend
7. Kindred Biosciences Announces Second Quarter 2014 Financial Results
8. Imprimis Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Operational Update
9. WuXi PharmaTech Announces Second-Quarter 2014 Results
10. Nutrastar International Inc. Announces Second Quarter 2014 Results
11. Novogen Announces Results of General Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ANN ARBOR, Mich. , Feb. 8, 2016 /PRNewswire-USNewswire/ ... Ann Arbor announced today that, as part ... will become one of the first hospitals in the ... Karin Muraszko , M.D., U-M,s chair of ... U-M,s chair of neurosurgery. --> The ...
(Date:2/8/2016)... 2016 Velano Vascular, a medical technology company ... and their practitioners, announced today that the company has ... use the proceeds from this financing, an extension of ... 2015, to support the development and commercialization of the ... Philadelphia , and a ...
(Date:2/8/2016)... 2016  HemaFlo Therapeutics, Inc. announced today that the United ... Number 9,119,880 covering the use of NephroFlow to treat acute ... HemaFlo,s founder, said, "We are pleased to secure our rights ... Peterson , PhD, HemaFlo,s founder, said, "We are pleased to ... --> Dale Peterson , PhD, HemaFlo,s founder, said, ...
Breaking Medicine Technology:
(Date:2/8/2016)... SC (PRWEB) , ... February 08, 2016 , ... Steve ... areas with a vital new community enrichment program, has teamed up with Citizens Opposed ... and children suffering from intimate abuse. To support all those victimized by the fear ...
(Date:2/8/2016)... ... ... Remember the old saying “rub some dirt on it”? Perhaps you should ... Bentonite Clay” the health benefits of integrating clay into a daily diet are numerous, ... former motivational speaker, Perry A~ has since dedicated her life to learning about the ...
(Date:2/8/2016)... ... February 08, 2016 , ... The ... important news! AHCC and the Home Health and Hospice ICD-10 Transition Workgroup are ... official ICD coding guidance and clarifications, to address concerns over the use of ...
(Date:2/8/2016)... ... 2016 , ... According to research by the National Association ... to be certified or obtain continuing education. To increase patient awareness of the ... Mouth?” campaign to inform dentists and patients about the possible lack of skills ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This ... an estimated 5000 perioperative nurses in attendance to study the latest evidence-based ...
Breaking Medicine News(10 mins):